KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Non-Current Assets (2019 - 2025)

Royalty Pharma's Non-Current Assets history spans 7 years, with the latest figure at $18.1 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 10.18% year-over-year to $18.1 billion; the TTM value through Dec 2025 reached $68.2 billion, up 9.37%, while the annual FY2025 figure was $18.1 billion, 10.18% up from the prior year.
  • Non-Current Assets for Q4 2025 was $18.1 billion at Royalty Pharma, up from $17.5 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $18.1 billion in Q4 2025 and bottomed at $13.5 billion in Q1 2021.
  • The 5-year median for Non-Current Assets is $14.8 billion (2021), against an average of $15.2 billion.
  • The largest annual shift saw Non-Current Assets dropped 7.85% in 2023 before it grew 15.01% in 2024.
  • A 5-year view of Non-Current Assets shows it stood at $14.6 billion in 2021, then decreased by 2.59% to $14.3 billion in 2022, then rose by 5.96% to $15.1 billion in 2023, then rose by 8.69% to $16.4 billion in 2024, then increased by 10.18% to $18.1 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Non-Current Assets are $18.1 billion (Q4 2025), $17.5 billion (Q3 2025), and $16.8 billion (Q2 2025).